Conjugation of biphenyl groups with poly(ethylene glycol) to enhance inhibitory effects on the PD-1/PD-L1 immune checkpoint interaction
Source abstract
Abstract
Monoclonal antibodies have been developed as anticancer agents to block immune checkpoint pathways associated with programmed cell death 1 (PD-1) and its ligand PD-L1. However, the high cost of antibodies has encouraged researchers to develop other inhibitor types. Here, biphenyl compounds were conjugated with poly(ethylene glycol) (PEG) to enhance the activity of small molecular inhibitors. Immunoassay results revealed the decrease in the inhibition activity following conjugation with linear PEG, suggesting that the PEG moiety reduced the interaction between the biphenyl structure and PD-L1. However, the inhibitory effect on PD-1/PD-L1 interaction was further enhanced by using branched PEG conjugates. The increase in the number of conjugated biphenyl compounds resulted in increased inhibitory activity. The highest IC50 value was 0.33 μM, which was about 5 times higher than that observed for a non-conjugated monovalent compound. The inhibitory activity was more than 20 times the activity reported for the starting compound. Considering the increase in the inhibition activity, this multivalent strategy can be useful in the design of new immune checkpoint inhibitors.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Cancer Immunotherapy and Biomarkers · Nanoplatforms for cancer theranostics · Peptidase Inhibition and Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Nano Medical Engineering Laboratory
RIKEN Cluster for Pioneering Research
Wako
Japan
Department of Life Science and Technology
Emergent Bioengineering Materials Research Team
RIKEN Center for Emergent Matter Science
Funding
Japan Society for the Promotion of Science
References (52)
Show source-provided references
1. Lee · J. Clin. Pharmacol. · 2016 · 56 · 15710.1002/jcph.591 ↗
2. Marin-Acevedo · J. Hematol. Oncol. · 2018 · 11 · 110.1186/s13045-017-0548-2 ↗
3. Rius · Oncogene · 2012 · 31 · 425710.1038/onc.2011.601 ↗
4. Dine · Asia-Pac. J. Oncol. Nurs. · 2017 · 4 · 12710.4103/apjon.apjon_4_17 ↗
5. Hoos · Nat. Rev. Drug Discovery · 2016 · 15 · 23510.1038/nrd.2015.35 ↗
6. Pardoll · Nat. Rev. Cancer · 2012 · 12 · 25210.1038/nrc3239 ↗
7. Iwai · J. Biomed. Sci. · 2017 · 24 · 110.1186/s12929-017-0329-9 ↗
8. Mellman · Nature · 2011 · 480 · 48010.1038/nature10673 ↗
9. Sharpe · Nat. Rev. Immunol. · 2018 · 18 · 15310.1038/nri.2017.108 ↗
10. Sun · Immunity · 2018 · 48 · 43410.1016/j.immuni.2018.03.014 ↗
11. Zhao · Cell Rep. · 2018 · 24 · 37910.1016/j.celrep.2018.06.054 ↗
12. Wu · Front. Immunol. · 2019 · 10 · 110.3389/fimmu.2019.00001 ↗
13. Dong · Nat. Med. · 2002 · 8 · 79310.1038/nm730 ↗
14. Dong · Nat. Med. · 1999 · 5 · 136510.1038/70932 ↗
15. Freeman · J. Exp. Med. · 2000 · 192 · 102710.1084/jem.192.7.1027 ↗
16. Jia · Cancer Biol. Med. · 2018 · 15 · 11610.20892/j.issn.2095-3941.2017.0086 ↗
17. Zitvogel · OncoImmunology · 2012 · 1 · 122310.4161/onci.21335 ↗
18. Postow · J. Clin. Oncol. · 2015 · 33 · 197410.1200/JCO.2014.59.4358 ↗
19. Weiner · Nat. Rev. Immunol. · 2010 · 10 · 31710.1038/nri2744 ↗
20. A. Grimsley , K. S.Shah and T.McKibbin , Pharmaceutical Biotechnology Fundamentals and Application , 4th edn, 2013 , vol. 12, pp. 337–359
21. Wang · Cancer Immunol. Res. · 2014 · 2 · 84610.1158/2326-6066.CIR-14-0040 ↗
22. McDermott · J. Clin. Oncol. · 2015 · 33 · 201310.1200/JCO.2014.58.1041 ↗
23. Chames · Br. J. Pharmacol. · 2009 · 157 · 22010.1111/j.1476-5381.2009.00190.x ↗
24. Shukla · Trends Biotechnol. · 2010 · 28 · 25310.1016/j.tibtech.2010.02.001 ↗
25. Wu · Acta Pharmacol. Sin. · 2020 · 1
26. Konstantinidou · Angew. Chem., Int. Ed. · 2018 · 57 · 484010.1002/anie.201710407 ↗
27. Musielak · Molecules · 2019 · 24 · 280410.3390/molecules24152804 ↗
28. Kim · Int. J. Mol. Sci. · 2020 · 21 · 363910.3390/ijms21103639 ↗
29. Huang · Bioconjugate Chem. · 2017 · 28 · 28310.1021/acs.bioconjchem.6b00651 ↗
30. Romero-Ben · J. Mater. Chem. B · 2019 · 7 · 593010.1039/C9TB01218D ↗
31. Ortiz Mellet · J. Mater. Chem. B · 2017 · 5 · 642810.1039/C7TB00860K ↗
32. Tjandra · Bioconjugate Chem. · 2019 · 30 · 50310.1021/acs.bioconjchem.8b00804 ↗
33. Bu · Nano Lett. · 2020 · 20 · 490110.1021/acs.nanolett.0c00953 ↗
34. Fasting · Angew. Chem., Int. Ed. · 2012 · 51 · 1047210.1002/anie.201201114 ↗
35. Pieters · Org. Biomol. Chem. · 2009 · 7 · 201310.1039/b901828j ↗
36. Li · J. Mater. Chem. B · 2019 · 7 · 137910.1039/C8TB03249A ↗
37. Zak · OncoTargets Ther. · 2016 · 7 · 3032310.18632/oncotarget.8730 ↗
38. Abagyan · J. Comput. Chem. · 1994 · 15 · 48810.1002/jcc.540150503 ↗
39. Bottegoni · J. Comput.-Aided Mol. Des. · 2008 · 22 · 31110.1007/s10822-008-9188-5 ↗
40. Bottegoni · J. Med. Chem. · 2009 · 52 · 39710.1021/jm8009958 ↗
41. Moser · Anal. Chem. · 2015 · 87 · 937610.1021/acs.analchem.5b02173 ↗
42. G. T. Hermanson , Bioconjugate techniques , Academic Press , 2013
43. Nair · Chem. Mater. · 2014 · 26 · 72410.1021/cm402180t ↗
44. Fairbanks · Macromol. Chem. Phys. · 2017 · 218 · 110.1002/macp.201700073 ↗
45. Skalniak · OncoTargets Ther. · 2017 · 8 · 7216710.18632/oncotarget.20050 ↗
46. Tan · Nat. Commun. · 2017 · 8 · 110.1038/s41467-016-0009-6 ↗
47. Arosio · Org. Biomol. Chem. · 2004 · 2 · 211310.1039/b405344c ↗
48. Munoz · J. Am. Chem. Soc. · 2013 · 135 · 596610.1021/ja400951g ↗
49. Fernandez-Villamarin · ChemNanoMat · 2016 · 2 · 43710.1002/cnma.201600008 ↗
50. Martin · Int. J. Nanomed. · 2018 · 13 · 524910.2147/IJN.S174673 ↗
51. Spaltenstein · J. Am. Chem. Soc. · 1991 · 113 · 68610.1021/ja00002a053 ↗
52. Terada · Polym. J. · 2017 · 49 · 25510.1038/pj.2016.99 ↗